v3.26.3
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Cash flows from operating activities:    
Net (loss) income including noncontrolling interests in subsidiaries $ (31,955) $ 19,697
Adjustments to reconcile net (loss) income including noncontrolling interests in subsidiaries to net cash provided by operating activities:    
Impairment of equity method investment 30,934 0
Depreciation, depletion and amortization 21,577 32,891
Accretion of asset retirement obligation 1,369 1,299
Gain on disposal of assets (487) 0
Compensation expense for share-based awards 2,367 3,751
Loss (gain) on foreign currency exchange 86 (405)
Change in fair value of equity securities 2,623 1,658
Gain on sale of equity securities (12,155) (3,512)
Unrealized loss (gain) on derivatives 9,691 (1,495)
Deferred income taxes (7,131) 3,609
Changes in operating assets and liabilities:    
Accounts receivable (5,326) (284)
Inventories 1,568 995
Prepaid expenses and other assets 2,362 (3,284)
Accounts payable and accrued expenses 7,204 5,455
Royalties and contingent legal fees payable (281) 1,529
Deferred revenue (162) 188
Net cash provided by operating activities 22,284 62,092
Cash flows from investing activities:    
Acquisition, net of cash acquired and working capital adjustments 0 1,230
Patent acquisition (1,750) 0
Purchases of equity securities (4,441) (17,368)
Sales of equity securities 27,738 15,165
Purchases of loans receivable 0 (3,364)
Proceeds from loans receivable 9,650 0
Purchases of property and equipment (2,137) (1,401)
Net additions to oil and gas properties (17,794) (8,961)
Proceeds from disposition of property and equipment 1,581 0
Net cash provided by (used in) investing activities 12,847 (14,699)
Cash flows from financing activities:    
Borrowings on the Benchmark revolving credit facility 0 4,000
Paydown of Benchmark revolving credit facility 0 (12,000)
Paydown of Deflecto Facility 1,763 12,100
Taxes paid related to net share settlement of share-based awards (3,096) (670)
Proceeds from exercise of stock options 0 30
Net cash used in financing activities (4,859) (20,740)
Effect of exchange rates on cash and cash equivalents (63) 1,247
Increase in cash and cash equivalents 30,209 27,900
Cash and cash equivalents, beginning of period 306,719 273,880
Cash and cash equivalents, end of period 336,928 301,780
Supplemental schedule of cash flow information:    
Patent acquisition of prepaid option $ 0 $ 15,000